Truist lowered the firm’s price target on AMN Healthcare to $105 from $140 but keeps a Buy rating on the shares as part of a broader research note on Healthcare Staffing. A survey of private companies indicated that both demand and price is trending lower sequentially in Travel Nursing, making new sales production less profitable while pressuring revenue/traveler/day metrics, gross margins and EBITDA margins in Q3, the analyst tells investors in a research note. A substantial improvement in full-time nurse retention year-to-date is a major driver of lower demand, Truist added.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMN:
- AMN Earnings this Week: How Will it Perform?
- Survey of 18,000 Nurses Shows Worsening Satisfaction and Wellbeing
- AMN Healthcare ESG Report Shows Industry-Leading Social Impact and Sustainability Efforts
- Report: Physicians Bill an Average of $3.8 Million a Year to Commercial Insurers
- AMN Healthcare to Hold First Quarter 2023 Earnings Conference Call on Thursday, May 4, 2023
Questions or Comments about the article? Write to editor@tipranks.com